Abstract
Chlamydia trachomatis is the most prevalent sexually transmitted bacterial infection worldwide and the leading cause of preventable blindness. Reports have emerged of treatment failure, suggesting a need to develop new antibiotics to battle Chlamydia infection. One possible candidate for a new treatment is the protease inhibitor JO146, which is an effective anti-Chlamydia agent that targets the CtHtrA protein. CtHtrA is a lynchpin on the chlamydial cell surface due to its essential and multifunctional roles in the bacteria's stress response, replicative phase of development, virulence and outer-membrane protein assembly. This review summarizes the current understanding of CtHtrA function and presents a mechanistic model that highlights CtHtrA as an effective target for anti-Chlamydia drug development.
Keywords:
DegP; HtrA; intracellular; protease; virulence.
Publication types
-
Review
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Anti-Bacterial Agents / pharmacology
-
Anti-Bacterial Agents / therapeutic use
-
Bacterial Outer Membrane Proteins / chemistry
-
Bacterial Outer Membrane Proteins / metabolism
-
Chlamydia Infections / drug therapy*
-
Chlamydia Infections / microbiology
-
Chlamydia trachomatis / drug effects
-
Chlamydia trachomatis / enzymology*
-
Chlamydia trachomatis / metabolism
-
Chlamydia trachomatis / pathogenicity
-
Dipeptides / therapeutic use
-
Humans
-
Models, Biological
-
Models, Molecular
-
Organophosphonates / therapeutic use
-
Protease Inhibitors / pharmacology
-
Protease Inhibitors / therapeutic use
-
Serine Endopeptidases / chemistry
-
Serine Endopeptidases / genetics
-
Serine Endopeptidases / metabolism*
-
Virulence Factors / chemistry
-
Virulence Factors / metabolism
Substances
-
Anti-Bacterial Agents
-
Bacterial Outer Membrane Proteins
-
Dipeptides
-
JO146 compound
-
Organophosphonates
-
Protease Inhibitors
-
Virulence Factors
-
Serine Endopeptidases